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A ligand-insensitive UNC5B splicing isoform
regulates angiogenesis by promoting apoptosis
Davide Pradella 1,2, Gianluca Deﬂorian 3,4, Alex Pezzotta5, Anna Di Matteo 1, Elisa Belloni 1,
Daniele Campolungo1,17, Andrea Paradisi 6, Mattia Bugatti7, William Vermi 7,8, Matteo Campioni9,
Antonella Chiapparino 9,18, Luigi Scietti9, Federico Forneris 9, Costanza Giampietro3,19, Nina Volf10,
Michael Rehman10,20, Serena Zacchigna 10,11, Maria Paola Paronetto 12,13, Anna Pistocchi5,
Anne Eichmann14,15,16, Patrick Mehlen6 & Claudia Ghigna 1 ✉

The Netrin-1 receptor UNC5B is an axon guidance regulator that is also expressed in
endothelial cells (ECs), where it ﬁnely controls developmental and tumor angiogenesis. In the
absence of Netrin-1, UNC5B induces apoptosis that is blocked upon Netrin-1 binding. Here,
we identify an UNC5B splicing isoform (called UNC5B-Δ8) expressed exclusively by ECs and
generated through exon skipping by NOVA2, an alternative splicing factor regulating vascular
development. We show that UNC5B-Δ8 is a constitutively pro-apoptotic splicing isoform
insensitive to Netrin-1 and required for speciﬁc blood vessel development in an apoptosisdependent manner. Like NOVA2, UNC5B-Δ8 is aberrantly expressed in colon cancer vasculature where its expression correlates with tumor angiogenesis and poor patient outcome.
Collectively, our data identify a mechanism controlling UNC5B’s necessary apoptotic function
in ECs and suggest that the NOVA2/UNC5B circuit represents a post-transcriptional
pathway regulating angiogenesis.
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lood vessels and nerves share a high degree of anatomical
similarity, hence the term neurovascular link1. Several axon
guidance regulators are also expressed by endothelial cells
(ECs) and control blood vessel morphogenesis2. These molecules,
which have a dual role in both the nervous and the vascular
system, have been termed angioneurins1.
A key angioneurin is the Unc-5 Netrin Receptor B (UNC5B)3,4.
UNC5B is a type I transmembrane protein and contains two
immunoglobulin-like (Ig) domains and two thrombospondin
type I (TSP) domains in its extracellular region, whereas its
cytoplasmic portion consists of a ZU5 domain (domain present in
Zonula Occludens 1 and UNC5 family), a DCC-binding motifcontaining domain, and a well-characterized death domain
(DD)5.
In developing blood vessels, UNC5B is present in tip cell
ﬁlopodia of endothelial sprouts, which closely resemble axonal
growth cones. There, it mediates the repulsive responses of Netrin
chemotropins4,6. In ECs, UNC5B acts also as a dependence
receptor, namely it induces apoptosis in the absence of its ligand
Netrin-1, whereas upon Netrin-1 binding it prevents apoptosis,
thus ﬁnely tuning developmental angiogenesis5,7,8.
Although the molecular mechanisms regulating UNC5Bmediated apoptosis are still poorly known, they are fundamental to understand important aspects of developmental as well
as tumor angiogenesis. Indeed, a correct balance between proapoptotic and antiapoptotic signals is critical to maintain blood
vessel integrity9–11. While several proangiogenic factors are
known to suppress apoptosis12, induction of apoptosis is a key
determinant during capillary formation and remodeling13,14, and
its inhibition reduces in vivo angiogenesis14. Recently, EC death
has been also described as an important mechanism that sustains
cancer progression15,16.
Alternative splicing (AS) is a post-transcriptional process
affecting nearly all human protein-coding genes. From a single
primary transcript (pre-mRNA) it generates multiple mature
mRNAs, producing protein isoforms with different structures,
functions, or localization17,18. AS events, such as inclusion or
skipping of speciﬁc exons, are controlled by the concerted action
of splicing regulatory factors (SRFs) binding to cis-acting motifs
located either in the regulated exons or within their ﬂanking
intronic sequences19. AS regulates key cellular processes during
organ development, where a multiple of splicing switches are
required for the acquisition of cell identity in adult tissues,
including erythropoiesis20, immune system maturation21,
neurogenesis23,
and
myoblast
spermatogenesis22,
24
differentiation . The relevance of AS is also underscored by the
observation that its deregulation leads to several human diseases,
including cancer25,26.
The current knowledge on the role of AS during vascular
development and angiogenesis is still limited. The Neurooncological ventral antigen 2 (NOVA2) is a tissue-restricted
SRF expressed by ECs of the blood vessels where it orchestrates
vascular morphogenesis27–29 and lymphatic EC speciﬁcation30.
NOVA2 is involved in multiple diseases. In addition to being a
target in several neurodegenerative disorders31,32, NOVA2
expression levels are speciﬁcally upregulated in tumor ECs, while
are not detectable in other cell types within the tumor tissue28,33.
In particular, NOVA2 overexpression also correlates with
reduced overall survival in ovarian cancer patients28, suggesting
that altered vascular NOVA2-mediated AS programs contribute
to phenotypic and functional abnormalities that characterize
tumor blood vessels34.
Here, we describe an UNC5B splicing isoform generated speciﬁcally in ECs as the result of a direct NOVA2-induced skipping
of exon 8, which we named UNC5B-Δ8. We found that UNC5BΔ8 is unable to transduce the Netrin-1 prosurvival signal and
2

regulates blood vessels formation in an apoptosis-dependent
manner. Moreover, UNC5B-Δ8 is aberrantly expressed by ECs of
human colon cancer vasculature, correlating with tumor angiogenesis and poor patient survival. Collectively, our results
strongly support a role for NOVA2 in controlling the dependence
receptor function of UNC5B in ECs and suggest that the
NOVA2/UNC5B axis may represents a post-transcriptional
pathway relevant to both developmental and tumor angiogenesis.
Results
Identiﬁcation of an UNC5B isoform generated by AS in the
endothelium. For the majority of protein isoforms generated
through AS in ECs, functional role remains obscure35. AS is
particularly frequent in cell-surface molecules and receptors, thus
potentially affecting interactome networks as well as downstream
signaling pathways36.
Given its importance in EC biology7,8, we investigated UNC5B
AS events in diverse vertebrate cell and tissue types, or
developmental stages, by using the Vertebrate Alternative
Splicing and Transcription Database (VastDB)37. We found a
single AS event conserved in human (HsaEX0069379), mouse
(MmuEX0050632), and chicken (GgaEX0006169). This event
affects UNC5B exon 8, whose exclusion from the mature mRNA
generates a shorter transcript herein named UNC5B-Δ8. Intriguingly, among several SRFs, we found a strong signiﬁcant inverse
correlation (r = −0.6849; P value < 0.0001) between the inclusion
of UNC5B exon 8 (Percent Spliced-In, PSI) and the expression of
NOVA2, an important regulator of vascular development27
(Supplementary Fig. 1a). Accordingly, by RNA-seq we found
that Unc5b-Δ8 production is one of the main AS events regulated
by NOVA2 in murine ECs (Fig. 1a-b). Thus, we decided to
investigate the relevance of UNC5B AS regulation in the
endothelium.
By RT-PCR analysis using RNA extracted from NOVA2
knockdown or overexpressing mouse ECs (moEC), we conﬁrmed
that NOVA2 depletion reduced the expression of Unc5b-Δ8
(Fig. 1c), whereas an opposite effect was obtained by forced
NOVA2 expression (Supplementary Fig. 1b). The NOVA2dependent production of Unc5b-Δ8 was also veriﬁed by
performing NOVA2 silencing in other two distinct immortalized
murine EC lines (Fig. 1d and Supplementary Fig. 1c). Similar
results were obtained also using human ECs (Fig. 1e and
Supplementary Fig. 1d). We have previously shown that NOVA2
expression is modulated by ECs density, being signiﬁcantly higher
in conﬂuent compared to sparse ECs27. Here, we found a similar
behavior also for UNC5B-Δ8 expression (Supplementary
Fig. 2a-c).
Additionally, UNC5B-Δ8 and NOVA2 levels increased during
in vitro angiogenesis, as evaluated by a tube formation assay on
Matrigel (Fig. 1f). Expression of COL4A1, a known marker of
endothelial differentiation38, also increased during the same time
frame (Supplementary Fig. 1e).
We extended the positive correlation between Unc5b-Δ8 and
Nova2 expression also to the vascular endothelium in vivo using
freshly isolated ECs from mouse lungs (Fig. 1g). While Unc5b
transcripts containing exon 8 (Unc5b-FL) are abundantly
expressed in the total colon, we found negligent Unc5b-Δ8
expression in the total colon but a marked expression in freshly
puriﬁed ECs (Fig. 1g).
Since vessels in the heart undergo signiﬁcant remodeling
perinatally39, we also interrogated cardiac ECs and found a
progressive increase in Unc5b-Δ8 and Nova2 expression during
mouse heart vasculature development (Fig. 1h).
Collectively, our results indicate that the AS proﬁle of UNC5B
is regulated in ECs in a NOVA2-dependent manner.
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Supplementary Fig. 3a). SpliceAid 2 (http://www.introni.it/
spliceaid.html)42 reported similar results (Supplementary
Fig. 3b). Importantly, the YCAY cluster position was consistent
with Unc5b splicing regulation, given the ability of NOVA2 to
induce exon skipping when bound upstream to the regulated AS
exon40. Notably, ﬁve out of seven of the top motifs identiﬁed in
mouse Unc5b pre-mRNA were conserved in human UNC5B premRNA (Fig. 2a; Supplementary Fig. 3c). To determine whether
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Fig. 1 Inclusion of UNC5B exon 8 is regulated in ECs. a Differentially spliced exonic events in NOVA2-depleted moEC compared to control moEC (NCBI
BioProject: PRJNA293346). Absolute difference of Percent Spliced-In (PSI) between means is shown. Unc5b exon 8 AS event is indicated in red. b
Schematic representation of the mouse and human UNC5B genomic region with the AS exon 8 of 33 nt (gray). Black boxes = constitutive exons; lines =
introns. Two different mRNAs result from the inclusion (red lines) or skipping (blue lines) of exon 8. Arrows indicate primers used for RT-PCR. c Left: RTqPCR (relative to Ubb) and immunoblotting of NOVA2 expression levels in NOVA2-depleted moEC. The anti-NOVA2-speciﬁc antibody recognizes two
immunoreactive bands at 50–55 kDa and 70–80 kDa, as previously reported27, 31; VINCULIN as loading control. Right: RT-PCR of Unc5b exon 8 AS proﬁle
in the above ECs. n = 3. d Nova2 mRNA (relative to mouse Ubb or human ACTB) and protein expression levels, and AS analysis of Unc5b exon 8 in another
murine EC line (luEC) (n = 3) and e in human immortalized ECs (HUVEC/TERT2) transfected with a siRNA against Nova2 or with a control siRNA.
VINCULIN as loading control. n = 5. f Left: in vitro angiogenesis assay of HUVEC/TERT2 plated on Matrigel-coated plates. Scale bar: 0.5 mm. Right:
NOVA2 mRNA expression levels (relative to B2M) and UNC5B exon 8 AS during differentiation of HUVEC/TERT2 and formation of capillary tube-like
structures on Matrigel. h = hours after seeding. n = 3. g Analysis, by RT-qPCR, of Nova2 mRNA expression levels (relative to Ubb) and, by RT-PCR, of
Unc5b exon 8 splicing in freshly puriﬁed ECs from mouse lung and colon tissue. n = 3. h Nova2 mRNA expression levels (relative to Ubb) and Unc5b exon 8
AS in primary ECs from mouse hearth (cardiac ECs) at different developmental stages: embryonic (E16–E18); neonatal (P0-P1); adult (P60). n = 3. The
percentage of exon inclusion is shown under each gel. n = biologically independent experiments. Two-tailed Student’s t-test or one-way ANOVA for
multiple comparisons; Error bars indicate ±SEM. Exact P values are indicated: *P < 0.05; **P < 0.01; ***P < 0.001; ns not signiﬁcant.
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7 and 9 in black. Introns 7 and 8 are also indicated (thin lines). YCAY sites, identiﬁed by using the RBPmap tool within 200 nt from the exon–intron junctions, are
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mouse Unc5b as in a. Arrows indicate primers used for RT-qPCR of NOVA2 immunoprecipitated RNAs. Lower: RT-qPCR of NOVA2 CLIP experiments in moEC.
Ampliﬁcation of immunoprecipitated RNAs with primers annealing to the YCAY cluster in intron 7 (A) and, as negative controls, within intron 8 (B and C). Error
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percentage of exon inclusion is shown below each gel. At least three independent biological replicates were analyzed for each experiment.

the YCAY cluster in Unc5b intron 7 represented a bona ﬁde
NOVA2 binding site, we performed UV crosslinking and
immunoprecipitation (CLIP), which detects direct protein-RNA
interactions in living cells43. RNA of UV crosslinked ECs was
4

immunoprecipitated using anti-NOVA2 or control antibodies.
RNAs bound by NOVA2 were then analyzed by RT-qPCR with
primers spanning either the YCAY cluster in Unc5b intron 7
(primers A) or intron 8 (primers B and C), used as controls
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(Fig. 2b). We found strong NOVA2 enrichment on the endogenous Unc5b pre-mRNA at the level of the YCAY cluster in
intron 7 (Fig. 2b).
To further investigate the role of NOVA2 in regulating Unc5b
splicing, we performed a splicing assay by using an
Unc5b minigene encompassing exons 7, 8, and 9 of the mouse
Unc5b gene along with the complete intervening intronic
sequences (Fig. 2c). The minigene was co-transfected in moEC
with plasmids encoding either NOVA2 or HNRNPA1, an SRF
abundantly expressed by ECs44, for which binding sites were not
detected in the sequence of mouse Unc5b by our RBPmap
analysis (Supplementary Fig. 3a). An empty plasmid was used as a
control. As showed in Fig. 2c, skipping of Unc5b exon 8 was
increased by NOVA2 overexpression. In contrast, HNRNPA1
overexpression had no effect, supporting a NOVA2-speciﬁc
effect. We also generated a mutated Unc5b minigene (p-Unc5b
Mut) in which YCAY motifs upstream exon 8 were replaced with
YAAY, a sequence not recognized by NOVA245. As showed in
Fig. 2d, mutations in the YCAY cluster reduced Unc5b-Δ8
production when NOVA2 was overexpressed (Fig. 2d). We also
performed an in vitro RNA pull-down to further assess the
sequence speciﬁc association of NOVA2 to Unc5b YCAY motifs
in intron 7. As showed in Supplementary Fig. 4a, NOVA2 was
able to interact with Unc5b intron 7 riboprobe containing the
YCAY cluster, but not with its mutated version (Supplementary
Fig. 4a).
Downstream Unc5b exon 8, our RBPmap analysis indicated the
presence of putative RBFOX2 binding sites, an SRF with a wellcharacterized role in ECs46. Nevertheless, silencing of RBFOX2
did not affect Unc5b splicing in moEC (Supplementary Fig. 4b)
further supporting the speciﬁcity of our results.
In summary, our ﬁndings demonstrate that NOVA2 promotes
skipping of UNC5B exon 8 by directly binding to the YCAY
cluster located upstream of this exon (Fig. 2e).
Unc5b-Δ8 is required for angiogenesis in vivo. Zebraﬁsh
represents a powerful model to study vertebrate vascular
development47. Moreover, the Nova2 RNA-binding domain is
94% identical in zebraﬁsh and humans, and ~50% of Novaregulated AS events are conserved from mouse to zebraﬁsh48. We
found that a cluster of YCAY motifs is also located upstream of
the zebraﬁsh unc5b exon 8 (Fig. 3a). Accordingly, we discovered
that the expression of the unc5b-Δ8 was co-regulated with nova2
levels during zebraﬁsh development (Fig. 3b). Morpholinomediated nova2 knockdown caused a reduction of unc5b-Δ8
production, which was partially rescued by the co-injection of a
morpholino-resistant nova2 mRNA, thus supporting a Nova2speciﬁc effect (Fig. 3c; Supplementary Fig. 5a). To validate these
ﬁndings, we used nova2 mutant ﬁsh generated by CRISPR/Cas
genome editing27. Notably, nova2 mutants displayed AS changes
of unc5b exon 8 comparable to those observed in nova2 morphants (Fig. 3d). Collectively, these results indicated that unc5b
exon 8 splicing is regulated by Nova2 in vivo in zebraﬁsh
embryos.
At the protein level, zebraﬁsh Unc5b shares 65% amino acid
identity with the human receptor49, with the highest percentage
identity (71%) in the netrin-binding Ig domains50. Unc5b
depletion in zebraﬁsh causes vessel development defects in
speciﬁc vascular beds. In unc5b morphants, inhibition of
parachordal vessel (PAV), formed by secondary sprouts emerging
from the posterior cardinal vein (PCV), is a highly penetrant
phenotype4,5,51 and it was attributed to dysregulated Unc5b
prodeath activity7. As showed in Fig. 3e, we conﬁrmed PAV
defects in unc5b morphants (Fig. 3e). By using PAV formation as
a readout of Unc5b function in vivo, we also found that co-
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injection of a morpholino-resistant unc5b-Δ8 mRNA in unc5b
morphants showed higher efﬁciency in restoring Unc5b vascular
activity compared to the full-length mRNA containing exon 8
(unc5b-FL) (Fig. 3e and Supplementary Fig. 5b-c). While
injections of increasing doses of unc5b-FL were not able to
restore PAV formation (Supplementary Fig. 5d-e), we were able
to observe an increase of PAV sprouting in zebraﬁsh embryos
injected with the maximal dose tested (Supplementary Fig. 5f).
PAV growth is also strongly inhibited in nova2 mutants at both
72 hours (hpf) and 6 days post-fertilization (dpf) (Fig. 3f and
Supplementary Fig. 6a), thus indicating complete abrogation of
PAV formation upon Nova2 depletion rather than a delay. The
drastic reduction of unc5b-Δ8 observed upon Nova2 depletion
(Fig. 3c-d) prompted us to evaluate the ability of unc5b-Δ8
mRNA injection to restore PAV formation also in a background
where the endogenous unc5b-FL isoform is expressed. Remarkably, we found that unc5b-Δ8 mRNA rescued PAV formation
defects of nova2 mutant (Fig. 3g), thus suggesting that Unc5b-Δ8,
but not Unc5b-FL isoform, is required for the formation of the
PAV during zebraﬁsh development.
To further investigate the function of Unc5b-Δ8 during
vascular development, we injected increasing doses of unc5b-Δ8
mRNA in wild-type zebraﬁsh embryos—where, differently from
rescue experiments of unc5b morphants (Fig. 3e), both Unc5b-FL
and Unc5b-Δ8 isoforms are present.
Forced expression of Unc5b-Δ8 caused several morphological
defects in a dose-dependent manner, including loss of arterialISV formation abnormalities and vessels defects in the plexus
region (Supplementary Fig. 6c-f).
Collectively, our results support the biological relevance of
Unc5b-Δ8 in the formation of several vascular beds and the
importance of a tight control of Unc5b-Δ8 production during
zebraﬁsh development. In particular, whereas Unc5b-Δ8 is
fundamental for the formation of the PAV during zebraﬁsh
development, its forced expression is detrimental for other
vasculature structures, including the ISVs and vessels in the
plexus region.
UNC5B-Δ8 prevents Netrin-1 prosurvival signaling. Apoptosis
plays a fundamental role in tissue remodeling during development through the removal of redundant cells. In the context of
vascular biology, apoptosis is involved in several cases of vessel
regression11 as well as in important aspects of angiogenic vessel
growth, including lumen formation52,53, EC sprouting54, and the
control of EC number and capillary diameter during vessel
maturation55.
In the absence of Netrin-1, UNC5B induces apoptosis through
its cytoplasmic death domain (DD). Instead, Netrin-1 ligand
binding triggers UNC5B multimerization leading to the inhibition of UNC5B prodeath activity8. In this latter condition, the
cytoplasmic region of UNC5B adopts a closed conformation5 and
interacts with an inactive, phosphorylated form of DeathAssociated-Protein kinase (DAPk)8. Conversely, in the absence
of Netrin-1, UNC5B adopts an open conformation that triggers
DAPk dephosphorylation (active form) and induction of
apoptosis8 (Fig. 4a).
Given the importance of cell death regulation for EC functions,
we investigated whether the NOVA2-dependent AS regulation of
UNC5B inﬂuence UNC5B cell death activity. We expressed the
two UNC5B AS variants, UNC5B-FL (with exon 8) and UNC5BΔ8 (lacking amino acid sequence Asn[356]- Pro[367], which are
substituted by a Thr[367] residue), fused to a C-terminal HA- or
GFP-tag. As showed in Fig. 4b, both variants were equally able to
reach the cell membrane of transduced HUVEC (Fig. 4b). Similar
results were obtained using other overexpressing ECs (such as
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are indicated: *P < 0.05;; ***P < 0.001; ****P < 0.0001; ns not signiﬁcant.

moEC) (Supplementary Fig. 7a). Since HeLa expresses no or very
little endogenous UNC5B (Supplementary Fig. 7b), we used these
cells for gain-of-function studies. Both UNC5B-FL and UNC5BΔ8 reached the cell membrane (Supplementary Fig. 7c) exposing
their Netrin-binding extracellular portion (Supplementary Fig. 7d)
in transiently transfected HeLa cells.
Next, using UNC5B isoforms fused to HA- or GFP-tag, we
tested the ability of these receptors to dimerize in the presence of
Netrin-156. As showed in Fig. 4c, UNC5B-Δ8 was able to properly
dimerize with other UNC5B-Δ8 receptors, as it has been reported

to occur for the UNC5B-FL isoform56 (Fig. 4c). Using surface
plasmon resonance (SPR), as previously reported57, we measured
similar Netrin-1-binding afﬁnities for the recombinant ectodomain fragments of both UNC5B variants (Supplementary Fig. 7e).
Hence, the absence of 11 amino acids (exon 8) in the extracellular
portion of UNC5B does not affect the ability of UNC5B-Δ8 to
form dimers or associate to its ligand Netrin-1.
Next, we tested if the absence of exon 8 could inﬂuence the
ability of Netrin-1 to block UNC5B-induced cell death7. As
showed in Fig. 4d and e, we conﬁrmed that Netrin-1 treatment
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blocks cell death induction by UNC5B-FL (Fig. 4d) and that this
effect is accompanied by an increase of the phospho-DAPk
(Fig. 4e), the UNC5B-mediator of apoptosis inactive in the
phosphorylated state7. We also found that Netrin-1 treatment
increased phospho-DAPk association to UNC5B-FL compared to
untreated cells (Fig. 4f and Supplementary Fig. 7f). Conversely,
cells expressing UNC5B-Δ8 were largely irresponsive to Netrin-1
treatment, as determined by: (i) cell death assays, (ii) levels of
phospho-DAPk; and (iii) the association of the latter with the
receptor (Fig. 4d-f). The conﬁrmation of these results in ECs
(such as HUVEC and moEC) (Supplementary Fig. 8a-d) strongly
suggests that NOVA2-mediated splicing of UNC5B exon 8
transforms the dependence receptor UNC5B in a constitutively
active proapoptotic variant.
During zebraﬁsh development, apoptosis occurs in transient
tissue- and cell-population-restricted waves58. To assess EC death
in the developing vascular system, we performed a terminal
deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling
(TUNEL) assay in zebraﬁsh embryos at different developmental
stages (Supplementary Fig. 9a-b). Dying ECs were detectable in
the zebraﬁsh trunk and tail regions at 30/33 hpf, a developmental
stage short before a second wave of sprouting emerges from the
PCV to remodel ISVs and form the PAV that occurs at 34 hpf
(Supplementary Fig. 9a-b). Notably, apoptotic cells were observed
in the region of the PCV from which the PAV originates—at 30
hpf—or where the PAV would arise—at 33 hpf. Apoptotic ECs
were also conﬁrmed by cleaved Caspase-3 immunostaining
(Supplementary Fig. 9c).
The ability of UNC5B to induce apoptosis is intimately
connected with its role in angiogenesis5. Indeed, an UNC5B
mutant in a constitutively open and proapoptotic conformation
stimulates the formation of speciﬁc blood vessels (such as PAV)
in zebraﬁsh embryos5. Since we found that Unc5b-Δ8 is required
for adequate PAV formation during zebraﬁsh development
(Fig. 3e) and its overexpression induced EC death in vivo
(Supplementary Fig. 8e), we tested whether apoptosis is required
for PAV formation.
Unc5b depletion reduced detectable EC death in zebraﬁsh
embryos, which was restored by unc5b-Δ8 mRNA injection.
Coherently, in co-injected embryos treated with different
apoptosis inhibitors, we were unable to detect dying ECs detected
by TUNEL assay (Supplementary Fig. 8f). Notably, inhibition of
apoptosis prevented the unc5b-Δ8 mRNA-mediated rescue of
PAV formation defects in unc5b morphants, without impairing
other blood vessels (Fig. 4g, Supplementary Fig. 8g).
Finally, we tested UNC5B-Δ8-depleted human ECs capacity to
form tube-like structures in two-dimensional matrices, a process
in which both pharmacological and genetic inhibition of
apoptosis prevent the formation of a mature network14. Notably,
UNC5B-Δ8 depletion by using a small interfering RNA (Fig. 4h)
or by using morpholino oligos sterically blocking NOVA2
binding on YCAY cluster located in intron 7 (Supplementary
Fig. 10a-d) signiﬁcantly reduces the tube formation capabilities.
In summary, our data indicate that UNC5B-Δ8 prevents
Netrin-1 prosurvival signaling and that its apoptotic activity is
necessary for angiogenesis.
NOVA2/UNC5B-Δ8 axis in ECs of colon cancer patient vasculature. Compared to normal blood vessels, NOVA2 expression
is upregulated in tumor ECs of colorectal and ovarian cancers,
whereas it is not detectable in other cell types within the
tumor28,33. Moreover, high NOVA2 expression correlates with
shorter overall ovarian cancer patient survival28.
By immunohistochemistry (IHC), we conﬁrmed NOVA2 selective
upregulation in ECs of colon adenocarcinoma vasculature and other
8

cancer types—including oral cavity and hepatocellular carcinomas—
compared to adjacent normal tissues (Fig. 5a; Supplementary
Fig. 11a-c and Supplementary Fig. 12a-b). Next, we performed an
in situ hybridization (ISH) by using a chromogenic BaseScope assay
able to speciﬁcally detect UNC5B-Δ8, but not the UNC5B-FL mRNA
(Supplementary Fig. 13a-b). According to EC-restricted NOVA2
expression in cancer specimens, we found that UNC5B-Δ8 was
present only in the tumor endothelium (Fig. 5a and Supplementary
Fig. 13c).
Using the UALCAN web-tool (http://ualcan.path.uab.edu)59 to
compare cancer and nonpathological samples from The Cancer
Genome Atlas (TCGA)60, we found that NOVA2 was upregulated
in colon cancer tissues versus not pathological counterparts
(Fig. 5b). NOVA2 upregulation was also conﬁrmed in colon
cancer microarray datasets from Oncomine (http://oncomine.org/
resource)61 (Supplementary Fig. 14a-b). RNA-seq TCGA dataset also showed a signiﬁcant decrease of UNC5B exon 8 inclusion in
colorectal cancers compared to the normal tissues (Fig. 5c).
Accordingly, a positive correlation (r = 0.406; P < 0.0001)
between UNC5B-Δ8 and NOVA2 expression levels was present
in the TCGA-Colon Adenocarcinoma (TCGA-COAD) dataset
(Fig. 5d). We validated these ﬁndings in a small cohort of colon
cancer patients by RT-PCR and RT-qPCR analysis by using RNA
extracted from: (i) colon cancer specimens, (ii) normal adjacent
colon tissue, and (iii) liver metastasis (Supplementary Fig. 14c-e).
A similar correlation was also found in liver hepatocarcinoma
(LIHC-TCGA) and head and neck tumors (HNSC-TCGA)
(Supplementary Fig. 12c-d), where our IHC analyses demonstrated EC-restricted NOVA2 expression. Expression levels of
both NOVA2 and UNC5B-Δ8 were also positively correlated with
the expression of a colon tumor-speciﬁc angiogenetic signature62
(r = 0.729 and r = 0.430; P < 0.0001) (Fig. 5e and f).
Clinical data annotated in the TCGA dataset (https://www.
cbioportal.org)63 and the Human Cancer Metastasis Database
(HCMDB) (https://hcmdb.i-sanger.com)64, showed NOVA2
upregulation in colon cancers with metastasis and/or recurrences
(Fig. 5g-h). Indeed, high NOVA2 expression was also associated
with shorter metastasis and relapse-free survival (Supplementary
Fig. 14f-g). We also found that high NOVA2 and UNC5B-Δ8
expression levels correlated with short overall survival in colon
cancer patients (Fig. 5i-l).
Recent evidence has shown that tumor cells are able to induce ECs
cell death, thus favoring metastasis dissemination16. Here, we were
able to detect positive apoptotic ECs within the tumor tissue, whereas
detection of apoptosis in the vasculature of the nonpathological
parenchyma was rare (Supplementary Fig. 15a-b). Notably, apoptotic
ECs showed a strong NOVA2 IHC signal. However, due to the
difﬁculty of detect EC-restricted apoptotic events in such a small
cellular population of the tumor microenvironment, our observations
do not allow us to directly evaluate the impact of EC apoptosis in the
disease progression.
Collectively, our results show that UNC5B-Δ8 and NOVA2 are
upregulated in colorectal tumor vasculature. Furthermore, the
correlation of UNC5B-Δ8 and NOVA2 expression with a tumor
angiogenic signature is in line with the possibility that the
NOVA2/UNC5B-Δ8 circuit plays a role also in the tumor
vascular niche. However, further studies are required to
better assess the contribution of UNC5B-Δ8 and NOVA2 to
tumor vascularization and metastasis.
Discussion
Tight regulation of the balance between proapoptotic and antiapoptotic signals is crucial to maintain blood vessel integrity and
stability9–11. While a number of proangiogenic factors prevent EC
apoptosis12, time- and spatial-restricted induction of apoptosis is
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Fig. 5 NOVA2 and UNC5B-Δ8 expression levels in colon cancer patients. a IHC of NOVA2 (I and III, scale bar: 60 μm) and ISH with the UNC5B-Δ8 probe
(II and IV, scale bar: 30 μm) in colon primary tumors and normal adjacent tissues. Black arrowheads indicate UNC5B-Δ8 signal in ECs in tumor blood
vessels. b RNA-seq data analysis of NOVA2 mRNA expression levels, c PSI (Percent Spliced-In) of UNC5B exon 8, and d correlation between NOVA2 and
UNC5B-Δ8 expression in normal (blue) and colon adenocarcinoma (red) samples in the TCGA-COAD dataset. e NOVA2 and f UNC5B-Δ8 correlation with
a colon tumor-speciﬁc angiogenetic signature (TEC). g NOVA2 mRNA Z-score expression levels in colon adenocarcinoma without (N0) or with metastasis
(N1 or N2) annotated in the TCGA-COAD dataset. h NOVA2 mRNA expression levels in colon adenocarcinoma without or with metastasis (GSE14095 and
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calculated by HCMDB platform. For correlation analysis, linear regression (black line) and Pearson r coefﬁcient with two-tailed P-value were also
calculated.

a key determinant during capillary morphogenesis and
remodeling13,14,65,66, and its inhibition reduces angiogenesis
in vivo14,65. In particular, a role for apoptosis in controlling EC
number, capillary diameter during angiogenic vessel growth, and
maturation has been reported55. Moreover, EC apoptosis is
instrumental in lumen formation during in vitro vessel-like
structure formation52 and in vivo, where apoptotic ECs have been
found during placenta vasculogenesis and angiogenesis
processes53. While the molecular machinery executing EC

apoptosis is relatively well known, much remains to be understood about how these pathways are regulated during physiological and pathological angiogenesis.
Here we describe an alternative splicing variant of the dependence
receptor UNC5B (UNC5B-Δ8) that is produced in ECs, is insensitive
to the prosurvival activity mediated by Netrin-1, and regulates vessel
formation in an apoptosis-dependent and vascular beds-speciﬁc
manner. These ﬁndings further support the notion that EC apoptosis
plays an important role during blood vessel morphogenesis67–69.
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In addition to its known role in axon repulsion and vascular
branching3,4, UNC5B acts as a dependence receptor, as it either
prevents or induces apoptosis, depending on Netrin-1 binding70.
Consequently, the UNC5B/Netrin-1 binding is intimately associated with activation of a cell survival signaling that ﬁnely tunes
developmental angiogenesis7.
We demonstrated that UNC5B is regulated through AS in ECs,
which is mediated by the splicing factor NOVA2 playing relevant
roles during angiogenesis and vascular differentiation27,30.
Mechanistically, we demonstrated that high NOVA2 expression
levels promote skipping of UNC5B exon 8 by directly binding to a
YCAY cluster located in intron 7. This splicing event removes 33
nucleotides encoding for a region predicted to be intrinsically
disordered (IDR), located in the extracellular domain proximal to
UNC5B transmembrane domain (Supplementary Fig. 16a-b).
Interestingly, 90% of AS events located in coding regions have no
homology with either functionally deﬁned protein domains or
regions with a deﬁned tertiary structure71,72. Moreover, AS
events of exons that encode for IDRs are frequently regulated in a
tissue-speciﬁc manner73,74. IDRs are commonly found in transmembrane proteins, where they contribute to proper receptor
organization, kinase activity, and activation of phosphatase signaling cascades75. In addition to providing binding sites for other
proteins, nucleic acids, or small molecule ligands74, IDRs ﬂexibility can favor conformational heterogeneity between structured
domains or harbor sites for post-translational modiﬁcations
(PTM), which ultimately alter downstream signaling through
recruitment of different effectors74. A salient example is provided
by the IDR linking two α-helices (α1-α2) of the antiapoptotic
protein Bcl-xL76, which acts as a ﬂexible loop and regulates
apoptosis by allosteric displacement of proapoptotic effectors
according to its PTM status76. Phosphorylation and deamination
of residues within the α1-α2 IDR promote its association with the
Bcl-xL core that in this closed conformation is not able to
associate with proapoptotic BH3 domain-containing proteins
(such as BIM) and p5376. We found that the lack of the IDR in
UNC5B-Δ8 does not affect its ability to correctly localize, bind
Netrin-1, or dimerize. Nevertheless, UNC5B-Δ8 is insensitive to
Netrin-1 prosurvival signal. In analogy to the IDR of Bcl-xL, we
hypothesize that the absence of the ﬂexibility provided by UNC5B
exon 8-encoded IDR could alter the cytoplasmic conformation of
UNC5B-Δ8 preventing the transduction of Netrin-1 signaling to
the cytoplasmic effector proteins (such as DAPk). Accordingly, in
UNC5B-Δ8 expressing cells, we found that the levels of the
inactive and phosphorylated form of DAPk77 does not respond to
Netrin-1 treatment.
The crystal structure of the UNC5B cytoplasmic domain has
provided fundamental cues for the elucidation of UNC5Bmediated signaling during apoptosis5. In particular, it has been
proposed that the ZU5, UPA, and DD domains can adopt two
possible conformations: in the close conformation, ZU5 is associated with both UPA and DD thus suppressing UNC5B capability to promote apoptosis, whereas release of this closed
conformation leads to the activation of apoptosis and blood vessel
patterning5. However, how Netrin-induced receptor dimerization
affects the intramolecular changes of these three distinctly folded
domains remains unsolved. In addition, we cannot rule out the
possibility that the IDR in UNC5B is involved in the formation of
a protein complex with other receptors or co-receptors that in
turn may impact Netrin-1 or additional UNC5B downstream
signaling. Thus, further studies are required to elucidate the role
of UNC5B IDR in regulating apoptosis.
In addition to UNC5B, NOVA2 regulates AS of pre-mRNAs
encoding for other Netrin-1 dependence receptors, such as DCC
and Neogenin78,79. In the case of DCC, NOVA2 promotes the
inclusion of an exon encoding the linker region between the two
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ﬁbronectin type III domains (FN4 and FN5) recognized by
Netrin-1, thus allowing an architectural switch in Netrin-1/DCC
receptor assembly78,80. Conversely, in Neogenin mRNA the exon
regulated by NOVA2 encodes for an IDR with unknown function
in the cytoplasmic tail of the receptor (Supplementary Fig. 17a).
Taken together, these observations suggest a widespread interplay
between NOVA2 and the dependence receptor family going
beyond their role in axon pathﬁnding in the central nervous
system and potentially affecting other tissues and developmental
processes where NOVA2 and dependence receptors are
expressed.
UNC5B and NOVA2 genes are highly conserved among different species, including zebraﬁsh48,50. In zebraﬁsh, AS of unc5b,
the IDR encoded by exon 8, and the position of the Nova2
binding sites are also conserved. These observations allowed us to
use zebraﬁsh as a model to assess the role of Nova2-mediated AS
regulation of unc5b in vivo. Several groups have reported PAV
formation defects in unc5b zebraﬁsh morphants4,5,51. Intriguingly, we found that unc5b-Δ8 is more efﬁcient in rescuing PAV
formation defects compared to unc5b-FL mRNA. Importantly, we
show that EC apoptosis occurs during zebraﬁsh development and
is regulated by Unc5b. In particular, Unc5b-Δ8 induces ECs
apoptosis in vivo, a biological process required for PAV formation, as demonstrated by the abolishment of unc5b-Δ8-mediated
PAV rescue in unc5b morphants treated with several apoptosis
inhibitors. These ﬁndings are in line with the observation that a
rat UNC5B mutant, which adopts a constitutively open and
proapoptotic conformation achieved by deletion of the ZU5
domain, is more potent than UNC5B-FL in restoring PAV formation defects of unc5b morphants5. Notably, the ability of rat
Unc5b-FL mRNA to restore PAV formation when injected at high
doses, as demonstrated by Wang and colleagues5, suggests that
modulation of Unc5b expression has a direct role on UNC5B
downstream signaling, possibly by overcoming Netrin-1 prosurvival signal. Our ﬁndings also suggest that the forced expression of Unc5b-Δ8, when the endogenous Unc5b is present, is
detrimental to the formation of a functional vascular network,
thus pointing out the importance of tight regulation of Unc5b-Δ8
expression for the proper development of different vascular
structures.
Here, we demonstrated that AS, by generating a Netrin-1 insensitive isoform, provides an additional tissue-speciﬁc layer of UNC5B
activity regulation bypassing Netrin-1 apoptotic inhibition.
Thus, the ability of UNC5B to regulate angiogenesis and its
apoptotic activity are intimately connected during vascular
development. However, it is important to note that the effects of
UNC5B reduction, differently from the depletion of pleiotropic
angiogenic regulators such as VEGFR281, occurs in a restricted
subset of ECs51 suggesting that UNC5B function(s), as well as
UNC5B AS-mediated regulation, could be required in a restricted
temporal and spatial manner. Furthermore, other apoptoticindependent UNC5B-DAPk downstream signaling may be differentially affected by the presence of exon 8 IDR, thus conferring
an additional layer of complexity to the molecular programs
regulating EC functions. Similarly, even if in our in vitro assays we
did not observe a difference in protein stability between UNC5BFL and UNC5B-Δ8, we cannot rule out the possibility that, in
speciﬁc vascular beds, the absence of exon 8 could alter UNC5BΔ8 protein half-live thus resulting in a more pronounced proapoptotic activity. Notably, since UNC5B-FL has a partial rescue
activity—at least at high doses—and UNC5B-Δ8 also partially
rescues PAV formation, it is possible that a certain ratio between
UNC5B-FL and UNC5B-Δ8 is required to achieve an optimal
proangiogenic activity. This ratio may be different depending on
the vessel type or localization, in line with our observation that
overexpressing UNC5B-Δ8 interferes with ISV formation.
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During cancer progression, the formation of metastasis
requires a multistep cascade involving tumor cells’ invasion of the
surrounding tissues, their intravasation and survival in the circulatory system, and ﬁnally their extravasation with the colonization of distant tissues. One centrally important process enabling
these steps is the tumor endothelium permeability, which for
example can be achieved by tumor ECs lacking intact cell-to-cell
contacts82–84. Intriguingly, several ﬁndings show that EC death is
another key process sustaining tumor endothelium fragility and,
as a consequence, promoting cancer progression and metastasis
formation85,86. Indeed, different mechanisms are exploited by
solid tumors to induce contact-dependent EC death that in turn
contributes to tumor cells escape in the blood circulation and
colonization of distant organs15,16,87–89. However, in addition to
providing the physical space for tumor cells to move across tissues or during vascular co-option90, ECs apoptosis has been
linked to the promotion of human endothelial progenitors
differentiation91 and initiation of EC sprouting54, thus suggesting
a widespread role in signaling or initiating angiogenic EC
responses.
Aberrant AS is a hallmark of cancer92. Several SRFs act as bona
ﬁde oncoproteins93 since their aberrant expression in tumor cells
could drive the production of AS isoforms involved in every
aspect of cancer cell biology, such as tumor establishment, progression, and resistance to therapeutic drugs26,92,94. Notably,
splicing aberrancies are not limited to the cancer cells but are also
evident in cells of the tumor microenvironment95. Remarkably,
an elevated number of AS errors are cancer restricted and particularly relevant for diagnosis, prognosis, and possibly to develop
more speciﬁc anticancer therapy94,96.
Here, we found that UNC5B-Δ8 and NOVA2 expression levels
are upregulated in ECs of the colon cancer vasculature, are
positively correlated to a colon-speciﬁc angiogenic signature62,
and are associated with a poor patient outcome. High NOVA2
expression is also associated with shorter metastasis and relapsefree survival. Hence, it is tempting to speculate that the NOVA2driven UNC5B-Δ8 production restricted to tumor ECs, may
represents a post-transcriptional mechanism favoring cancer cells
dissemination.
Collectively, our results demonstrated the existence of a posttranscriptional pathway relevant for blood vessel formation.
Furthermore, our preliminary and correlative observations suggest a possible role of the UNC5B-Δ8/NOVA2 axis also in tumor
angiogenesis. However the complete elucidation of UNC5B-Δ8
and apoptosis roles in the tumor vasculature context requires
further studies.
Nevertheless, our ﬁndings provide a perspective to understand
the molecular underpinnings sustaining the phenotypic and
functional aberrancies characteristic of tumor blood vessels,
which could be leveraged to develop innovative prognostic markers or more proﬁcient antiangiogenic therapies.
Methods
Cell culture. Mouse embryonic EC (moEC), previously referred to as vascular
endothelial (VE) cadherin-positive ECs, were described in97. Mouse lung-derived
luEC and lu2EC were described in refs. 98 and99, respectively.
Culture medium of moEC and lu2EC was DMEM (w/glucose 4.5 g/l w/o LGlutamine; Lonza, #LOBE12614F) supplemented with 10% fetal bovine serum
(FBS; Euroclone, #ECS0180L), L-Glutamine (2 mM, Euroclone, #ECB3000D),
penicillin/streptomycin (100 U/l, Euroclone, #ECB3001D), HEPES (25 mM,
Euroclone, #ECM0180), heparin (100 μg ml/l, from porcine intestinal mucosa;
Sigma–Aldrich #H3149), and EC growth supplement (ECGS; 5 μg/ml,
Sigma–Aldrich, E2759). The same medium, supplemented with puromycin
(3 μg/ml; InvivoGen, #ant-pr-1) or Hygromycin (50 ng/ml; Santa Cruz
Biotechnology, #sc-29067), was used for stable moEC depleted or overexpressing
NOVA227 or carrying inducible Unc5b-FL-GFP, Unc5b-Δ8-GFP, or GFP cDNAs.
LuEC were cultured in MCDB131 medium (Sigma–Aldrich; #M8537)
supplemented with 20% FBS, L-Glutamine (2 mM), sodium pyruvate (1 mM),
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heparin (100 μg/ml) and ECGS (5 μg/ml). moEC, lu2EC, and HUVEC/TERT2 were
grown as sparse or conﬂuent by placing 500,000 cells in 100 mm and 35 mm Petri
dishes, respectively. Since NOVA2 mRNA and protein levels are regulated by EC
density27, for the analysis of UNC5B splicing, NOVA2-depleted ECs were used as
conﬂuent monolayers, whereas overexpressing HA-tagged NOVA2 ECs were
grown as sparse.
Primary human umbilical vein endothelial cells (HUVECs) were obtained from
either Yale University Vascular Biology and Therapeutics Core Facility or
purchased (Lonza, #CC-2519) and maintained in EGM2-BulletKit medium (Lonza,
#CC-3156 and #CC-4176). The cells were veriﬁed through CD31 and VE-cadherin
staining for EC identity.
Immortalized HUVEC (HUVEC/TERT2) were purchased from Evericyte and
grown according to supplier instructions in EBM basal medium (Lonza, #CC-3156)
with selected supplements from EGM SingleQuot Kit (Lonza, #CC-4133) (BBE,
HEGF, hydrocortisone solution, and ascorbic acid solution), with 10% FBS, and
Geneticin (20 μg/ml, Gibco; #10131-019).
Primary cardiac ECs were puriﬁed from murine hearts as described in ref. 100
and maintained in EGM2-BulletKit medium (Lonza, #CC-3156 and #CC-4176).
To favor ECs attachment on plastic surfaces, dishes and ﬂasks were coated with
Gelatin (0.1% in PBS, Difco).
Culture medium of human cervix carcinoma (HeLa) cells (ATCC, CCL-2),
human embryonic kidney (HEK) 293 T cells, and HEK-293A cells (ATCC, CRL1573) was DMEM high-glucose (w/ 4.5 g/l w/o L-Glutamine) with 10% FBS, LGlutamine (4 mM), penicillin/streptomycin (100 U/l). NIH/3T3 mouse ﬁbroblast
cells were grown in DMEM glucose (w/ 4.5 g/l w/o L-Glutamine) with 10% FBS, LGlutamine (2 mM), penicillin/streptomycin (100 U/l).
Secreted, recombinant UNC5B-FL and UNC5B-Δ8 ectodomain fragments were
produced using FreeStyle™ HEK-293F cells (Life Technologies) cultured in
suspension using FreeStyle™ medium (Life Technologies).
All cells were free of mycoplasma contamination. Cells were maintained in a
humidiﬁed, 5% CO2 atmosphere at 37 °C.

Zebraﬁsh strains and maintenance. Zebraﬁsh (Danio rerio) experiments were
carried out in the zebraﬁsh facilities of the FIRC Institute of Molecular Oncology
(IFOM) and University of Milan. Zebraﬁsh from wild-type AB, transgenic Tg(kdrl:
GFP)la116 101, Tg(ﬂi1a:GFP)y1 102, and Tg(kdrl:GFP)la116;nova2io011 27 strains were
maintained and bred according to standard procedures and national guidelines
(Italian decree “4 March 2014, n.26”). All experiments were approved by the Italian
Ministry of Health and were performed under the supervision of the institutional
organism for animal welfare (Cogentech OPBA). Embryos were collected by natural spawning, staged according to Kimmel and colleagues, and raised at 28 °C in
ﬁsh water (Instant Ocean, 0.1% Methylene Blue) in Petri dishes, according to
established techniques. Generation of nova2 CRISPR/Cas9 x Tg(kdrl:GFP)la116
mutants (nova2io011) was described in ref. 27.

Plasmids. Mouse Unc5b-FL, ampliﬁed by using primers Unc5b-For-HindIII and
Unc5b-Rev-EcoRI-GFP and moEC cDNA, was cloned in pEGFP-N1 vector (Clonentech) to add an in-frame C-terminal GFP-tag. Mouse Unc5b-Δ8 was generated
by PCR-mediated mutagenesis of Unc5b-FL by using primers Unc5b-deletion_E8-F
and Unc5b-deletion_E8-R. Primers Unc5b-For-HindIII and Unc5b-rev-EcoRI- HA
were used to generate C-terminal HA-tagged Unc5b-FL and Unc5b-Δ8 cDNAs
cloned in the pcDNA3.1(−) vector (Invitrogen; # V79520).
Gateway technology (Gateway LR clonase II, Invitrogen; #11791) was used to
generate lentiviral vectors expressing the Unc5b cDNAs under the control of a Teton inducible promoter. To this purpose, Unc5b-FL-GFP, Unc5b-Δ8-GFP, or GFP
cDNAs were cloned into the pEN-Tmcs vector103 and then transferred in the
pSLIK-Hygro plasmid (Addgene, #25737)103. The same technology was used to
clone in the adenoviral construct pAd/CMV/V5/DEST (Invitrogen; #11791) the
GFP-tagged Unc5b cDNAs, which were previously subcloned into the pENTR11
vector (Invitrogen; #A10467).
To generate Unc5b wild-type minigene, the Unc5b genomic region
encompassing exons 7 and 9 was PCR ampliﬁed from mouse ﬁbroblast DNA with
primers Unc5b_minigene_F and Unc5b_minigene_R and cloned into the pcDNA3.1
(+) vector (Thermo Fisher, #V790-20). Mutated Unc5b minigene was generated by
site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Fisher,
#F541) with primers Unc5b_minigene_mut_F and Unc5b_minigene_mut_R.
Morpholino-resistant zebraﬁsh unc5b-FL and unc5b-Δ8 cDNAs, ampliﬁed with
primers Unc5b_zebraﬁsh-F/Unc5b_zebraﬁsh-R and an RT reaction generated with
RNA extracted from Tg(Kdrl:GFP) la116 embryos at 72 hpf, were cloned in a
modiﬁed pCS2+ (RZDP) vector in-frame C-terminal mCherry tag. The plasmid
expressing DAPk and L1CAM were described in75 and28, respectively.
For secreted recombinant protein production using HEK-293F cells we used the
pHLSec-UNC5B-FL vector56, kindly provided by Prof. Elena Seiradake, and
generated the corresponding pHLSec-UNC5B-Δ8 through site-directed
mutagenesis, using primers Unc5bEcto-deletion_E8-F and Unc5bEcto-deletion_E8R. Primers used for cloning experiments, RT-PCR, and RT-qPCR are listed in
Supplementary Table 1. All constructs were veriﬁed by sequencing.
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Lentivirus and adenovirus production and transduction. For lentivirus production HEK-293T cells were seeded in DMEM supplemented with 10% FBS
without antibiotics in 60 mm Petri dishes. The day after, cells at 60–70% conﬂuence
were transfected with 5 μg of packaging plasmid, 5 μg of envelope plasmid, and 20
μg of lentiviral vectors carrying the Unc5b cDNAs. After 18 h, the medium was
replaced with DMEM supplemented with 20% FBS and 1% penicillin/streptomycin. Cells were incubated for an additional 24 h and the medium containing the
lentiviral particles was harvested, ﬁltered using a 0.45 μm ﬁlter unit, and used to
infect ECs. For viral transduction, moEC were seeded in 100 mm Petri dishes and
infected at 70% of conﬂuence. These cells were incubated overnight with the viral
supernatant supplemented with 0.2 mM proline and polybrene (ﬁnal concentration
8 μg/ml; Sigma–Aldrich). After 48 h, hygromycin selection (50 μg/ml) was started
and continued until all noninfected control cells died.
Adenovirus production was performed into HEK-293A cells seeded in 100 mm
Petri dishes in DMEM medium without antibiotics. After 24 h, HEK-293A (at the
50–70% of conﬂuence) were transfected with the adenoviral constructs carrying the
Unc5b-GFP cDNAs (previously linearized with PacI) by using Lipofectamine 2000
(Invitrogen; #11668027). On day 3 after seeding, the medium was replaced and,
after additional 12 days, cell supernatant was collected and frozen at −80 °C. Upon
three cycles of freeze and thaw, medium containing the adenoviral particles was
harvested, sterile-ﬁltered, and used to infect HUVECs. Adenoviral infection was
performed by incubating ECs with the viral supernatant for 24 h.
Plasmid transfection. HeLa and moEC were transiently transfected with Lipofectamine 3000 (Invitrogen; #L3000001), according to the manufacturer’s protocol.
Brieﬂy, cells were seeded in a 6-well or 12-well plate to reach 70–75% of conﬂuence
the day of the transfection.
For recombinant UNC5B ectodomains production, HEK-293F cells were
transfected at a conﬂuence of 106 cells/ml, using 1 μg of plasmid DNA and 3 μg of
linear polyethyleneimine 25,000 Da (PEI; Polysciences). Four hours after
transfection, cell cultures were supplemented with Primatone® RL (Sigma–Aldrich)
at a ﬁnal concentration of 0.6%.
siRNA-mediated RNA interference. RNA interference was carried out on ECs
using Lipofectamine RNAiMAX (Invitrogen; #13778030) following the supplier’s
protocol. Brieﬂy, HUVEC/TERT2, luEC, and lu2EC were transfected at 80–90%
conﬂuence with the indicated siRNAs. HUVEC/TERT2 were silenced with a siRNA
against the human NOVA2 gene (MISSION siRNA ID SASI_Hs01_00220812;
Sigma–Aldrich), mouse Nova2 gene (MISSION siRNA ID SASI_Mm01_0094763;
Sigma–Aldrich) human UNC5B-Δ8 transcript (CUGUGCAUGCAAAUGCUGGAdTdT/UCCAGCAUUUGCAUGCACAGdTdT), or with a control siRNA
(MISSION siRNA Universal Negative Control #1; Sigma–Aldrich). Two subsequent transfections (with 24 h intervals) were performed with 30 nM of each
siRNA. Cells were collected 48 h after the second transfection. To obtain HUVECs
stably expressing shRNA-NOVA2, we produce lentiviral vectors in HEK-293T, as
above. Lentiviruses expressing a scramble sequence (shCtr) were used as control. At
48 h after transduction, HUVECs were selected using puromycin (1 μg/ml).
Morpholino treatment of human ECs. Conﬂuent (90%) HUVEC/TERT2 were
transfected with MO-i7_UNC5B oligonucleotide (Gene Tools) at 15 μM plus 6 μM
Endo-Porter PEG system (Gene Tools) according to the manufacturer’s instructions. A standard control oligonucleotide (Gene Tools) was used as control. After
36 h cells were detached and seeded in Matrigel-coated plates for tube formation
capability evaluation. UNC5B AS was evaluated after 48 h of morpholino treatment.
Morpholino oligo sequences are listed in Supplementary Table 2.
In vitro tube formation assay. To assess the ability of ECs to organize in a
capillary-like network, 30,000 HUVEC/TERT2 cells were plated in complete
medium on a 48-well plate coated with 100 μl/well of Growth Factor-Reduced
Matrigel (BD Biosciences, #356231). Tube-like structures were manually counted
under the microscope at the indicated timepoints. Tube-like structure formation of
UNC5B-Δ8-depleted HUVEC/TERT2 was evaluated in 96-well plate coated with
50 μl/well of Matrigel in complete medium at least 24 h after the last siRNA
transfection or 36 h after morpholino treatment.
Cell imaging. Transiently transfected HeLa cells were ﬁxed with 4% paraformaldehyde (PFA; Sigma–Aldrich). Nuclei were stained with 0.1 g/ml DAPI
(Sigma–Aldrich). The same protocol was also used for transduced ECs (moEC and
HUVEC), which were seeded in 35 mm Petri dishes coated with 0.1% Gelatin. For
imaging, an epiﬂuorescence microscope (Optical Microscope Olympus IX71)
equipped with ×4 or ×60 objectives was used. Photomicrographs were taken with a
digital camera Cool SNAPES (Photometrics). Data acquisition was done using the
MetaMorph 7.7.5 software (Universal Imaging Corporation). Images were exported
to Photoshop (Adobe). No manipulations were performed other than adjustments
in brightness and contrast. High-resolution pictures were acquired using a Leica
SP5 confocal microscope with a Leica spectral detection system (Leica 15 SP
detector) and the Leica application suite advanced ﬂuorescence software or Zeiss
LSM800 confocal microscope and Zeiss Zen 2.3 Software.
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RNA extraction, RT-PCR, and RT-qPCR. Total RNA was isolated using the
RNeasy Mini Kit (QIAGEN, #74106) according to the manufacturer’s instructions.
Total RNA was extracted from matrigel-based tube-like structures by using the
ReliaPrepTM RNA Miniprep System (Promega, #Z6011) according to the manufacturer’s instructions (#AN296). Total RNA from wild-type AB, Tg(ﬂi1a:GFP)y1,
nova2 morpholino-mediated knockdown Tg(ﬂi1a:GFP)y1 embryos, and Tg(kdrl:
GFP)la116;nova2io011 mutants were extracted with TRIzol reagent (Invitrogen.
#15596026) and puriﬁed with the RNeasy Mini Kit (QIAGEN, #74106).
Human primary colorectal cancer, adjacent normal colorectal, and liver
metastasis snap-frozen tissue samples were obtained from Biological Resource
Centre (CRB, Centre de Resource Biologique) of Léon Bérard cancer Centre (Lyon,
France) (protocol number: BB-0033-00050), as previously described104. CRB
medical and scientiﬁc committee approved the protocol. All patients signed
informed consent according to the French laws. Total RNA was extracted with
RNeasy Mini QIAcube Kit (Qiagen, #74116), following the manufacturer’s
protocol. RNA amount and quality were evaluated by NanoDrop 1000
Spectrophotometer (Thermo Scientiﬁc) and TapeStation System (Agilent
Technologies), respectively.
After treatment with DNAse I (Ambion, #AM2222), 0.5–1.5 μg of puriﬁed RNA
was retro-transcribed with a mix of oligos d(T)18 and random hexamers by using
SuperScript IV First-strand System (Invitrogen, #18091050). Resulting cDNA
(1/20 v/v) was then PCR ampliﬁed with the GoTaq G2 Flexi DNA Polymerase
(Promega, #M7805) according to the manufacturer’s instructions. For RT-qPCR,
an aliquot of the RT reaction was analyzed with QuantiTect SYBR Green PCR
(QIAGEN, #204145) by using LyghtCycler 480 (Roche). Target transcript levels
were normalized to those of the indicated reference genes. The expression of each
gene was measured in at least three independent experiments. All PCR products
were sequenced and bands intensity was quantiﬁed with NIH Image J software
(version 1.48 v). The percentage of exon inclusion was calculated as the ratio
between the intensity of the band with the alternative exon included and the
intensity of all bands.
RNA-binding protein target motifs prediction. RBP motifs prediction was performed by using RBPmap web server (http://rbpmap.technion.ac.il)41. Human and
mouse UNC5B pre-mRNA sequences at exon 8 splice junctions, extending 200
nucleotides into introns and 50 nucleotides into exons, were analyzed for human/
mouse motifs. The same pre-mRNA regions were analyzed by using SpliceAid 2
(http://www.introni.it/spliceaid.html)42.
Minigene splicing assay. Unc5b minigenes (wild-type or mutated) were cotransfected into moEC with protein expression vectors (HA-NOVA2 or T7HNRNPA1, previously generated in our laboratory27,103,105 or empty vector at 1:1
ratio by using Lipofectamine 3000. After 24 h, total RNA and protein lysates were
collected.
In vitro RNA pull-down assay. RNA probes containing the identiﬁed cluster of
NOVA2 binding sites in mouse Unc5b intron 7 or the same region in which YCAY
sites were substituted with YAAY tetranucleotides to prevent NOVA2 binding were
generated with the following set of primers: T7_YCAYcluster_F/ TDP43_
YCAYcluster _R.
Sense and antisense oligos carried a T7 polymerase promoter sequence and a
consensus-binding motif for TDP-43, respectively. cDNA template for in vitro
transcription was generated with Platinum SuperFi Green DNA polymerase
(Thermo Fischer Scientiﬁc, #12357-010) and used (1 μg) for in vitro synthesis of
RNA transcripts using the MAXIscript T7 Transcription Kit Life (Technologies,
#AM1312) according to the manufacturer’s protocol. Unincorporated nucleotides
were removed through two successive ammonium acetate/ethanol precipitations.
Next, 40 pmol of unlabeled RNA were biotinylated at the 3’ terminus using the
Pierce RNA 3’ End Biotinylation kit (Thermo Fisher Scientiﬁc, #20160) following
the manufacturer’s instructions.
For in vitro pull-down assays biotinylated RNA probes were resuspended in
250 μl of 2× TENT buffer (20 mM Tris-HCl pH 8; 2 mM EDTA; 500 mM NaCl; 1%
Triton X-100), protease inhibitors (Roche, cOmplete Mini; #11836170001), RNAse
inhibitor (SUPERase In, Ambion, AM2694), and 250 μl of cell lysates of NOVA2HA overexpressing HeLa cells for 30 min at RT. Seventy-ﬁve microliters of high
capacity streptavidin agarose resin (Thermo Fischer Scientiﬁc, #20357) was added
to the mixture and incubated for an additional 30 min at RT with intermittent
mixing every 5 min. Beads were then pelleted (2000 × g at 4 °C) and washed four
times in 1× TENT buffer. Elution of proteins bound to RNA probes was performed
in 2× SDS-sample buffer (120 mM Tris/HCl pH 6.8; 20% glycerol; 4% SDS, 0.04%
bromophenol blue; 10% β-mercaptoethanol) and by heating the samples at 95 °C
for 10 min. Standard western blotting techniques were used to detect NOVA2-HA
and TDP-43 in the pull-down.
Vital exclusion dye assay. HeLa cells were transfected and serum-starved
(Complete DMEM with 0.2% FBS) after 24 h. Mouse recombinant Netrin-1 (150
ng/ml in PBS/0.2% BSA, Bovin Serum Albumin; R&D) or the equivalent amount of
PBS/0.2% BSA were added during starvation. Collected cells were then incubated
(5 min) with a vital exclusion dye (Erythrosin B, 0.05% in PBS), which is
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impermeable to biological membranes106, and counted for positive and negative
staining. Percentage of cell death was calculated as the number of Erythrosin Bpositive cells with respect to the total. Cell death index is the ratio between the
percentage of cell death of each sample and the control (GFP untreated). moEC
plated at 70% of conﬂuence were induced with Doxycycline (1 μ/ml) in a serumstarved medium (Complete DMEM with 0.2% FBS; w/o ECGS) for 6 or 24 h and
then tested with the same procedure described for HeLa cells.
Caspase-3 activity assay. Caspase-3 activity was determined using the “Caspase
Glo 3/7” luminescence assay (Promega; #G8090) in a Synergytm HT Microplate
reader (BioTeK Instruments). Brieﬂy, 10,000 HUVEC were seeded in a 96-well
plate and transduced with the indicated adenovirus. The next day, cells were
serum-starved (EBM2 medium with 0.2% FBS), treated with mouse recombinant
Netrin-1 (150 ng/ml) or the equivalent amount of PBS/0.2% BSA, and assayed 8 h
for Caspase-3 activity following manufacturing instructions.
Co-immunoprecipitation. Co-immunoprecipitation assays were carried in HeLa
cells transiently co-transfected with plasmids expressing UNC5B isoforms or DAPk
(described in ref. 56) and treated with Netrin-1 (150 ng/ml) or PBS/0.2% BSA for
30 min (UNC5B dimerization) or 3 h (DAPk interaction). Adherent cells were
washed with ice-cold PBS and collected in an IP Buffer (50 mM HEPES pH 7.6,
150 mM NaCl, 5 mM EDTA, and 0.1% NP-40 with the addition of protease and
phosphatase inhibitors). GFP-tagged UNC5B splicing variants were immunoprecipitated using GFP-trap magnetic beads (Chromotek; #gtma) for 1 h at 4 °C.
Magnetic beads were washed three times in Wash Buffer (50 mM HEPES pH 7.6,
150 mM NaCl, 5 mM EDTA) and immunoprecipitated proteins were eluted in a 2×
SDS-sample buffer (120 mM Tris/Cl pH 6.8; 20% glycerol; 4% SDS, 0.04% bromophenol blue; 10% β-mercaptoethanol) by heating at 95 °C for 10 min. Half of the
eluted proteins were loaded in an SDS-PAGE gel and analyzed by immunoblotting
with the indicated antibodies. As a negative control, GFP-tagged Unc5b-FL were
immunoprecipitated with aspeciﬁc magnetic beads.
Protein surface biotinylation. UNC5B-FL-HA, UNC5B-Δ8-HA, and L1CAM-HA
overexpressing HeLa cells were incubated with EZ-Link Sulfo-NHS-SS-Biotin (Life
Technologies, #21331) 0.2 mg/ml in chilled CM-PBS at 4 °C for 30 min. After three
washes (10 min each) in quenching buffer (100 mM glycine, 2.5 mM CaCl2, 1 mM
Mg2Cl2 in PBS) cells were collected by scraping and lysed in RIPA buffer (1%
Triton X- 100, 1% Sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 59
mM NaF, 160 mM NaCl, and 20 mM Tris-HCl, pH 7.4) supplemented with protease inhibitors (PI) (cOmplete™ and EDTA-free Protease Inhibitor cocktail;
Roche). Biotinylated proteins were retrieved by using Pierce High Capacity
Streptavidin agarose beads (Life Technologies, #20359). After three washed in
RIPA + PI buffer, biotinylated proteins were eluted in a 2× SDS-sample buffer by
heating at 95 °C for 10 min. Eluted proteins were loaded in an SDS-PAGE gel and
analyzed by immunoblotting with the indicated antibodies. A small fraction of
protein lysate for each condition was saved as an input fraction.
Immunoblot analysis. Cells were lysed in Laemmli buffer, supplemented with
protease and phosphatase inhibitors (cOmplete™ and EDTA-free Protease Inhibitor
cocktail; Roche). Proteins were separated in SDS-PAGE and analyzed by western
blotting by standard procedures. After protein transfer, the nitrocellulose membranes (0.45 μm; Whatman PROTRAN) were blocked by incubation with 5% nonfat dry milk. The following primary antibodies were used: anti-NOVA2 C-16
(1:200; Santa Cruz Biotechnology, #sc-10546), anti-α-TUBULIN (1:100,000;
Sigma–Aldrich, #T9026), anti-haemagglutinin (HA; 1:1,000; Roche,
#11867423001), anti-GAPDH (1:5,000; Abcam, #ab75834), anti-GFP (1:3,000;
Millipore, #MAB3580); anti-Cleaved Caspase-3 (1:1,000; Cell Signaling, #9661);
anti-VINCULIN (1:5,000; Millipore, #MAB3574); anti-UNC5B (1:1,000; Cell Signaling, #13851), anti-DAPk pSer308 (1:100,000; Sigma–Aldrich, #D4941); antiDAPk (1:1000; Sigma–Aldrich. #D1319); anti-T7 (1:1,000; Novagen, #69522-3);
anti-RBFOX2 (1:2,000; Bethyl Laboratories, #A300-864A); anti-mCherry (1:1,000;
Chromotek, #5f8); TDP-43 (1:1,000; Proteintech, #10782-2-AP). The following
secondary antibodies linked to horseradish peroxidase (Jackson Immuno Research)
were used: anti-Mouse (1:5,000; #115-035-146), anti-Goat (1:5,000; #705-035-147),
anti-Rat (1:5,000; #112-035-175) and anti-Rabbit (1:10,000; #711-035-152).
Immunostained bands were detected using the chemiluminescent method (Euroclone, LiteAblot Plus/Extended, #EMP011005/#EMP013001).
Morpholino and mRNA injections of zebraﬁsh embryo. Zebraﬁsh nova2 morphants were previously described in ref. 27. For unc5b knockdown, zebraﬁsh
embryos at one- to two-cell stage were injected with an unc5b morpholino antisense oligonucleotide (MO-unc5b) designed to block splicing of intron 1 as
described by Lu and colleagues4. Morpholino efﬁciency was evaluated by RT-PCR
with RNA extracted from 72 hpf embryos and with primers annealing in unc5b
exon 1 and intron 1. Capped zebraﬁsh unc5b-FL and unc5b-Δ8 mRNAs were
transcribed in vitro by using the SP6 mMessage mMachine kit (Ambion;
#AM1340) and co-injected with MO-unc5b (0.03 pmol/embryo) in one-cell stage
zebraﬁsh embryos. unc5b-Δ8 mRNA was also injected in Tg(ﬂi1a:GFP)y1 zebraﬁsh
embryos following the same experimental procedure. When not differentially
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indicated 100 pg of mRNA per embryo have been injected. Where indicated, 40 nM
BAF (Boc-d-FMK; Axon Medchem, #EC2158), 50 μM Q-VD-OPh hydrate (Adooq
Bioscience; #A14915), or 300 μM Z-VAD-FMK (ApexBio Technology; #A1902)
were added in the E3 medium 4 h after MO-unc5b and unc5b-Δ8 mRNA coinjection.
Evaluation of vascular defects was performed by immunoﬂuorescence staining
of zebraﬁsh embryos. Tg(kdrl:GFP)la116 and Tg(ﬂi1a:GFP)y1 zebraﬁsh embryos at
the indicated developmental stage were dechorionated and ﬁxed in 4% PFA in PBS,
overnight (ON) at 4 °C. Embryos were then washed four times for 5 min in PBST
(PBS, 0.1% Tween 20). Permeabilization in PSBT with 0.5% Triton X-100 was
performed for 30 min at room temperature (RT). Embryos were then blocked for 2
h at RT in a solution of PBST plus 0.5% Triton X-100, 10% normal goat serum and
1% BSA. Embryos were then incubated with primary antibodies in blocking
solution ON at 4 °C. Successively, embryos were washed six times in PBST over 4 h
at RT and then incubated with secondary antibodies in blocking solution, ON at
4 °C. Embryos were washed six times in PBST over 4 h at RT and equilibrated in
glycerol 85% in PBS. The following antibodies were used: anti-GFP (1:2,000;
Millipore, #MAB3580); anti-mouse Alexa-488-conjugated IgG (1:400; Thermo
Fischer Scientiﬁc, #A-32766); anti-cleaved Caspase-3 (1:200; Cell Signaling, #9661).
For the microscope analysis, we mounted on slides the trunk and tail regions
dissected from ﬁve to six embryos of each samples. Images were taken with a Leica
TCS SP2 confocal microscope, using oil-immersion objective. The same mounting
procedures and magniﬁcations were used when comparing the different
experimental groups of each experiment. At least 20 embryos of each sample were
dissected to mount on slide trunk and tail regions.
To rescue vascular defects of nova2 mutants, one- to two-cell stage embryos
from heterozygous nova2 mutants were injected with in vitro transcribed unc5b-FL
and unc5b-Δ8 mRNAs. At 72 hpf, embryos were analyzed by immunoﬂuorescence
staining; for each biological experiment at least 20 embryos of each sample were
dissected to mount on slide trunk and tail regions.
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling
(TUNEL) assay. EC death in Tg(kdrl:GFP) la116 and Tg(ﬂi1a:GFP)y1 embryos at
different developmental stages was evaluated by using the Invitrogen™ Click-iT™
Plus TUNEL Assay for In Situ Apoptosis Detection, Alexa Fluor™ 647 dye (Invitrogen; #C10619) following manufacturer’s instructions. TUNEL staining was
validated in 24 hpf Tg(ﬂi1a:GFP)y1 zebraﬁsh embryos treated with DNAse (provided in the kit). Brieﬂy, embryos were ﬁxed in 2% PFA and dehydrated in absolute
methanol ON at −20 °C. Embryos were then rehydrated, washed with PBST and
permeabilized for 30 min with proteinase-K. Embryos were then ﬁxed in 2% PFA
20 min, washed in PBST and treated 10 min with TdT reaction buffer. After
incubation with TdT reaction cocktail for 1 h at 37 °C embryos were washed in 3%
BSA in PBST and incubated in Click-IT reaction cocktail 30 min at RT. Embryos
were ﬁnally washed six times in PBST over 4 h, equilibrated in glycerol 85% in PBS
and mounted for confocal acquisition. For GFP detection, anti-mouse Alexa-488conjugated IgG (1:400, Thermo Fischer Scientiﬁc, #A-32766) was used following
manufacturers instructions.
Crosslinking and immunoprecipitation (CLIP). CLIP assay was performed as
previously described28,107,108,109. Brieﬂy, moEC were irradiated with 150 mJ/cm2 in
a Stratlinker 2400 at 254 nm. After centrifugation at 1,300 × g for 3 min, cell pellet
was incubated for 10 min on ice with lysis buffer [50 mM Tris-HCl, pH 7.4,
100 mM NaCl, 1% Igepal CA-630 (Sigma–Aldrich), 0.1% SDS, 0.5% sodium
deoxycholate, 0.5 mM Na3VO4, 1 mM DTT, protease inhibitor cocktail
(Sigma–Aldrich), and RNase inhibitor (Promega)]. Samples were brieﬂy sonicated
and incubated with 10 μl of 1:1,000 RNase I (100 U/µl, Ambion) dilution and 2 μl
of DNase (2 U/µl, Ambion) for 3 min at 37 °C shaking at 100 × g, and then centrifuged at 15,000 × g for 10 min at 4 °C. The amount of 1 mg of extract was
immunoprecipitated using anti-NOVA2 C-16 (1:200; Santa Cruz Biotechnology,
#sc-10546) antibody or puriﬁed IgG (negative control) in the presence of protein
A/G magnetic Dynabeads (Life Technologies). Immunoprecipitates were incubated
ON at 4 °C under constant rotation. After stringent washes with high salt buffer
(50 mM Tris-HCl, pH 7.4, 1 M NaCl, 1 mM EDTA, 1% Igepal CA-630, 0.1% SDS,
0.5% sodium deoxycholate), beads were equilibrated with PK buffer (100 mM TrisHCl, pH 7.4, 50 mM NaCl, 10 mM EDTA). An aliquot (10%) was kept as input
lysates, while the rest was treated with 50 µg Proteinase-K and incubated for 20 min
at 37 °C shaking at 100 × g. 7 M urea was added to the PK buffer and incubation
was performed for further 20 min at 37 °C and 100 × g. The solution was collected
and phenol/CHCl3 (Ambion) was added. After incubation for 5 min at 30 °C
shaking at 100 × g, phases were separated by spinning for 5 min at 17,000 × g at RT.
The aqueous layer was transferred into a new tube and precipitated by the addition
of 0.5 μl glycoblue (Ambion), 3 M sodium acetate pH 5.5, and 100% ethanol. After
mixing, the solution containing retained RNA was precipitated ON at −20 °C.
RNA extracted from both the input material and the immunoprecipitates was then
analyzed by RT-qPCR as described in the above paragraph. The binding was
expressed as a percentage of the input material.
Production of the UNC5B-FL and UNC5B-Δ8 ectodomain recombinant protein. Suspension-cultured HEK-293F cells transfected using either pHLSec-
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UNC5B-FL or pHLSec-UNC5B-Δ8 plasmids were harvested 6 days after transfection by 10 min centrifugation at 1,000 × g110. The supernatant containing
secreted UNC5B variants was loaded at 0.5 ml/min on a 1 ml HisTrap Excel 5 mL
column (GE Healthcare). The column was washed with 10 column volumes of
buffer A, composed of 50 mM HEPES, 500 mM NaCl, pH 8.0. Nonspeciﬁcally
bound material was washed out by supplementing 35 mM imidazole to buffer A.
Elution of the sample of interest was obtained by increasing the imidazole concentration to 250 mM. The elution peak protein was concentrated by centrifugation
using Vivaspin® Turbo 15, 30,000 MWCO centrifugal ﬁlters (Sartorius) to a
volume less than 500 μl and then loaded onto a Superdex 200 10/300 GL (GE
Healthcare) gel ﬁltration column equilibrated with 50 mM HEPES, 200 mM NaCl,
pH 8.0. Both samples yielded single peak elutions corresponding to the UNC5B
variants as assessed by SDS-PAGE analysis. Peak fractions were collected and
further concentrated to 1 mg/ml. The puriﬁed samples were then ﬂash-frozen in
liquid nitrogen and stored at −80 °C until further usage.
Surface Plasmon Resonance. Surface Plasmon Resonance analyses were carried
out on a BIAcore T200 (GE Healthcare) instrument at 25 °C. Netrin-1 (Netrin-1Fc; ProSci, #90-261) was immobilized on a Protein G sensor chip (GE Healthcare)
through injection at a concentration of 30 μg/ml. Recombinant UNC5B-FL and
UNC5B-Δ8 ectodomains analytes, prepared in PBS, 0.005% Tween 20, were
injected at different concentrations (0–10 μM) using a 30 μl/min ﬂow rate. Proteins
were allowed to associate for 120 sec and to dissociate for 600 sec. Data were
processed with the BIAcore BIAevaluation software v. 3.0.
Tissues and immunohistochemistry. Tissues sections of tissue microarray
(TMACCR) slides were obtained from a set of colorectal carcinomas (n = 67) and
included cases with (n = 33) or without (n = 34) KRAS mutations on exon 12 or
13. Clinical samples were represented by a multitumor TMA (including cores from
126 primary carcinomas) and parafﬁn tissue blocks from archival colorectal carcinomas were retrieved from the archive of Pathology (U.O. Anatomia Patologica,
Spedali Civili di Brescia). The study supervised by W.V., was approved by the local
IRB (code: WW-IMMUNOCANCERhum, NP-906). Full sections from carcinoma
of the oral cavity (n = 5) and hepatocellular carcinoma (n = 5) were included in the
analysis. Sections of 4 µm were obtained for immunohistochemistry by using antiNOVA2 (polyclonal rabbit, 1:100; Sigma–Aldrich, #HPA045607). Antigen retrieval
was performed using EDTA Buffer (pH 8.0) whereas signal detection was obtained
using Novolink Polymer System (Novocastra) followed by DAB. Anti NOVA2 was
combined with anti-CD31 (clone PECAM-1, 1:100, Leica; #CD31-PECAM-1) and
anti-Cleaved Caspase-3 (polyclonal rabbit, 1:600, R&D Systems; #AF835). For
double staining, after completing the ﬁrst immune reaction, the second was
visualized using Mach 4 MR-AP (BIOCARE MEDICAL), followed by Ferangi Blue
(BIOCARE MEDICAL). For triple immunohistochemistry, the third immune
reaction was revealed using Mach 4 MR-AP (Biocare Medical), followed by
ImmPACT Vector Red Substrate Kit, Alkaline Phosphatase (VECTOR
LABORATORIES).
Validation of Cleaved Caspase-3 antibody used for triple
immunohistochemistry analysis was performed in Burkitt’s Lymphoma, a tumorcell population know to display high rates of apoptosis in vivo109,107, and Reactive
lymph nodes, as control. Isotype and omission controls on colorectal carcinomas
sections are also shown.
Digital microscopy. Stained slides were acquired using the Aperio CS2 digital
scanner and ScanScope software (Leica Biosystems, Wetzlar, Germany). Images
were viewed and organized using ImageScope software (Leica biosystems, Wetzlar,
Germany). Region of interest consisted of the tumor area and normal colon;
necrotic areas were excluded from the selection. IHC Nuclear Image Analysis
algorithm (Leica biosystems, Wetzlar, Germany) was setup for the analysis to
identify categories of strong and weak positive cells based on the signal intensity
(Supplementary Fig. 18). Data are expressed as the absolute number of NOVA2positive cells per mm2 and as fractions of strong and weak positive cells.
Chromogenic BaseScope RNA in situ hybridization. A custom-designed speciﬁc
probe targeting UNC5B-tv2-E7E8 (gene accession NM_001244889, 1452–1491 bp)
was obtained by design a 1ZZ probe against human Unc5b exon 7-exon 9 junction;
a control probe was represented by Hs-PPIB-3zz probe. All probes and BaseScope
reagents were purchased from Advanced Cell Diagnostic (ACD). The reaction was
revealed using the BaseScope TM detection Reagents v2-RED (#323910). Cell
blocks obtained by NIH/3T3 murine cells transfected with human UNC5B-Δ8 were
used as a positive control; negative controls were represented by murine NIH/3T3
murine cells transfected with human UNC5B-FL or empty vector. 4 µm sections
obtained from TMACCR and control cell blocks were baked in a 60 °C oven for
30 min and deparafﬁnized in three changes of xylene and three changes of absolute
alcohol. The sections were blocked with 3% H2O2 (#322381) for 10 min at RT and
washed with deionized water. Target retrieval was performed in a controlled water
bath with ACD target retrieval solution (#322000) at 98 °C for 15 min. A permeabilization step was included using protease III (#322380) with incubation in a
humidiﬁed chamber (30 min for FFPE tissue and 15 min for cell pellets) in a 40 °C
oven (HB-1000, Hybridizer, UVP Cambridge, England). After washing with
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deionized water the target probe and the housekeeping gene-positive control probe
were incubated for 2 h in a humidiﬁed chamber in a 40 °C oven (HB-1000
Hybridizer, UVP, Cambridge, England). A subsequent series of ampliﬁcation steps
were performed according to the protocol as follows: Ampliﬁcation AMP1 (30 min
at 40 °C), AMP2 (30 min at 40 °C), AMP3 (15 min at 40 °C), AMP4 (30 min at
40 °C), AMP5 (30 min at 40 °C), AMP6 (15 min at 40 °C) with the humidiﬁed
chamber and AMP7 (30 min at RT) and AMP8 (15 min at RT). Slides were washed
twice for 2 min in between each ampliﬁcation step using diluted washing buffer
(#310091). Chromogenic detection was performed with FAST RED-B (#322919)
diluted 1:60 in FAST RED-A buffer (#322918) incubated for 10 min at RT. Nuclear
counterstaining was performed with Mayer’s hematoxylin. Finally, slides were
covered using glycerol.
Gene expression and splicing analyses of transcriptomic data. TCGA-COAD,
TCGA-LIHC, and TCGA-HNSC cancer omics data were analyzed by using the
UALCAN (http://ualcan.path.uab.edu)59, a web-portal allowing gene expression
analysis of selected genes in TCGA level 3 RNA-seq data corresponding to primary
tumors and normal samples. Transcripts per million (TPM) were used to generate
boxplots. Data are visualized representing interquartile ranges (minimum, 25th
percentile, median, 75th percentile, maximum). Outliers are excluded. UALCAN
also provides an estimate of the statistically signiﬁcant difference in gene expression levels between groups by employing TPM values and a t-test.
Gene expression data were also retrieved by using Oncomine (http://oncomine.
org/resource/)61. Colon adenocarcinoma microarray databases with altered
NOVA2 gene expression were ﬁltered considering their signiﬁcance (P value <
0.05). The following probes are shown in Supplementary Fig. 14a-b:
A_23_P101609 (TCGA Colorectal Dataset) and 206476_s_at (Kaiser Dataset). 90th
percentile, 75th percentile, median, 25th percentile, 10th percentile are represented.
UNC5B mRNA splicing patterns (inclusion of exon 8) were analyzed by using
TCGA SpliceSeq (http://projects.insilico.us.com/TCGASpliceSeq)111, a web-based
resource that provides Percent Spliced-In (PSI) values for splicing events on
samples from the TCGA-COAD, TCGA-LIHC, and TCGA-HNSC level 3 datasets.
Metastasis status information, as speciﬁed by the neoplasm disease lymph node
stage of the American joint committee on cancer code (N0, N1, or N2), of colon
adenocarcinoma patients (TCGA, Firehose Legacy) were retrieved by using
cBioPortal for Cancer Genomics (https://www.cbioportal.org)63. Associated mRNA
expression Z-scores (RNA-Seq V2 RSEM) were plotted according to the presence
of lymph node metastasis (N1, N1a, N1b, N1c, N2, N2a, and N2b status) or
absence (N0). Additional colorectal cancer datasets with metastasis information
were retrieved by using the Human Cancer Metastasis Database (HCMDB)
(https://hcmdb.i-sanger.com), which directly provides differentially expressed
genes between different types of samples64.
Correlation analyses. Correlation analyses were performed by using Pearson’s
correlation method. The Vertebrate Alternative Splicing and Transcription Database (VastDB; http://vastdb.crg.eu/)37 was used to retrieve human UNC5B exon 8
PSI values and SRSF1, NOVA2, HNRNPA1, SRSF3, HNRNPC, or RBFOX2 cRPKM
expression values in 71 sets of tissues, cell types, and developmental stages. Sets in
which UNC5B exon 8 PSI values were not reported or quality scores do not meet
the minimum threshold were excluded.
TSVdb web-tool (http://www.tsvdb.com)112 was used to obtain UNC5B-Δ8
isoform-speciﬁc expression (not available with TCGA SpliceSeq) in colon
adenocarcinomas of TCGA-COAD dataset (RSEM values, RNA-Seq by
Expectation Maximization). Gene expression of NOVA2 and genes of the colon
tumor-speciﬁc angiogenetic signature (CD59, COL4A1, HMGB1, COL4A1, HEYL,
IGFBP7, PPAP2B, SPARC, ARPC2, LDHB, PHC3, POMP, VIM) were also retrieved
with TSVdb. The tumor-speciﬁc angiogenetic signature was calculated as the
average of normalized gene expression level (relative to the mean of expression in
the TCGA-COAD dataset) of each gene of the signature.
Survival analyses. Overall survival curves of colon cancer patients were generated
by analyzing clinical data (overall survival and survival status) in patients with
colon adenocarcinoma of the TCGA-COAD dataset. Patients were stratiﬁed
according to UNC5B-Δ8 and NOVA2 RSEM expression values in: High (>3rd
quartile), Medium (between 3rd and 1st quartile), Low (<1st quartile). The logrank Mantel-Cox test was employed to determine any statistical difference between
the survival curves. Clinical data, UNC5B-Δ8 isoform-speciﬁc, and NOVA2
expression data were obtained from TSVdb (http://www.tsvdb.com). Metastasisfree and Relapse-free survival curves showed in Supplementary Fig. 14 were
obtained by using the PROGgeneV2 tool (http://genomics.jefferson.edu/
proggene)113. Patients were bifurcated based on the 75th percentile in high NOVA2
expression (>75th) or low NOVA2 expression (<75th).
Identiﬁcation of intrinsically disordered regions (IDR). Intrinsically disordered
regions in UNC5B protein sequence were retrieved by using the following bioinformatic tools: (i) GlobPlot prediction analysis (http://globplot.embl.de)114 and (ii)
PONDR prediction (http://www.pondr.com) using VLS2 algorithm optimized for
long and short disordered regions115. Speciﬁcally, GlobPlot prediction analysis was
performed using Russell/Linding propensity with the following parameters:
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minimum peak width (5) and maximum join distance (4) in disorder prediction;
minimum domain length (74) and maximum linker length (15) in globular domain
hunting with SMART/Pfam domain prediction; smoothing settings were 10 for 1st
and 2nd derivative Savitzky-Golay frame. Prediction of natural disordered regions
(PONDR) was performed by using the VLS2 algorithm. PONDR VSL2 predictor is
a combination of neural network predictors optimized for long (>30 residues) and
short (≤30 residues) disordered regions.
Statistics and reproducibility. Paired or unpaired Student’s two-tailed t-test and
one-way ANOVA (corrected for multiple comparisons, Turkey test), were used to
compare two or more groups, respectively, and to determine statistical signiﬁcance
(GraphPad Prism 6). When not differently indicated the mean value of each
condition is shown. For survival analysis, the Log-rank test for trend was performed. Differences were considered signiﬁcant at P value <0.05. When not differently indicated, three independent biological experiments were analysed (Fig.:
4b-c and 4e-f; Supplementary Figs.: 5b, 5c, 7c, 7f, 10b). Validation of BaseScope
probe, TUNEL analysis, and Cleaved Caspase-3 IHC analysis was performed in
parallel to the experimental conditions.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The previously published RNA-sequencing data of Nova2 knockdown and control ECs
used in this study are available in the NCBI BioProject under accession code
PRJNA293346 (ID: 293346)27. All gene and transcripts data, patient’s survival, and
clinical information that support the ﬁndings of this study are available in GDC Data
Portal (https://portal.gdc.cancer.gov/projects/TCGA-COAD), ONCOMINE (htttp://
www.oncomine.org), HCMDB databases (https://hcmdb.i-sanger.com), PROGgeneV2
tool (http://genomics.jefferson.edu/proggene), and TSVdb web-tool (http://www.tsvdb.
com), VastDB (https://vastdb.crg.eu/wiki/Main_Page). Speciﬁc accession codes to
original raw data used in this study include: GSE14095, GSE87211, GSE28722,
GSE31595, and GSE28814. Source data are provided with this paper.

Materials availability
Materials are available from the authors upon reasonable request.
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